anti-VEGF antisense oligonucleotides (Novagali)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-VEGF antisense oligonucleotides (Novagali)

Drug Alias NameNOVA-21012NOVA-21013

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionVascular endothelial growth factor receptor antagonistsAntisense oligonucleotide inhibitors

TargetsVascular endothelial growth factor receptor

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSanten Sas

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesSanten Sas

Active IndicationsN/A

Inactive IndicationsMacular Degeneration

ATC CodeN/A